Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study

IMPORTANCE: Intravitreous bevacizumab (0.25 to 0.625 mg) is increasingly used to treat type 1 retinopathy of prematurity (ROP), but there remain concerns about systemic toxicity. A much lower dose may be effective while reducing systemic risk. OBJECTIVE: To find a dose of intravitreous bevacizumab t...

Full description

Saved in:
Bibliographic Details
Published in:JAMA Ophthalmol
Main Authors: Wallace, David K., Kraker, Raymond T., Freedman, Sharon F., Crouch, Eric R., Hutchinson, Amy K., Bhatt, Amit R., Rogers, David L., Yang, Michael B., Haider, Kathryn M., VanderVeen, Deborah K., Siatkowski, R. Michael, Dean, Trevano W., Beck, Roy W., Repka, Michael X., Smith, Lois, Good, William V., Hartnett, Mary Elizabeth, Kong, Lingkun, Holmes, Jonathan M.
Format: Artigo
Language:Inglês
Published: 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5521814/
https://ncbi.nlm.nih.gov/pubmed/28448664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2017.1055
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items